Tyme Technologies Inc. (TYME)

[Inoviorulez]

3rd line pancreatic cancer phase 2 pivotal is going to start Q3

2nd line pancreatic cancer phase 2 pivotal Precision Promise is going to start Q3. The goal with Precision Promise is to start

A.)monotherapy SM-88 first in 2nd line PC patients
B.) then SM-88/chemo combo for 1st line PC patients soon after 2nd line starts

Q3 of 2019 is July - September of 2019. That means these pivotal studies are intended to be started between these months, pending there is no type of delay.

Final prostate cancer phase 2 data is expected 2nd half of 2019

Update On TYME-18 IND expected 2nd half of 2019

Preclinical data using SM-88 for 15 cancer types expected 2nd half of 2019.